GSE218097 SOX10 overexpression glial cell 2 v 1 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE218097_SOX10 overexpression_glial cell_2_v_1_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE218097_SOX10 overexpression_glial cell_2_v_1_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE218097_SOX10 overexpression_glial cell_2_v_1_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE218097_SOX10 overexpression_glial cell_2_v_1_human_up.

Results found

Linked to

 

Label

Description

 

Gene

acetylserotonin O-methyltransferase like

Gene

ral guanine nucleotide dissociation stimulator like 2

Gene

HLA complex P5

Gene

A-kinase anchoring protein 17A

Gene

H3.3 histone A

Gene

ribosomal protein SA 2

Gene

GOLGA2 pseudogene 7

Gene

non-coding RNA activated by DNA damage

Gene

general transcription factor IIi pseudogene 4

Gene

CASTOR family member 3, pseudogene

  • Gene

    acetylserotonin O-methyltransferase like


  • Gene

    ral guanine nucleotide dissociation stimulator like 2



  • Gene

    A-kinase anchoring protein 17A



  • Gene

    ribosomal protein SA 2


  • Gene

    GOLGA2 pseudogene 7


  • Gene

    non-coding RNA activated by DNA damage


  • Gene

    general transcription factor IIi pseudogene 4


  • Gene

    CASTOR family member 3, pseudogene

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.